Figure 3.

(A) Overview plot depicting the complete clinical course of all patients within sub-cohort C, including the results of longitudinal ctDNA analysis. Patients with metastatic disease are marked with an asterisk “*” symbol. Blue diamond reflects initial/primary surgery performed to build the personalized ctDNA assay, all other additional surgeries are represented with grey diamonds. (B) Distribution of pathogenic and likely pathogenic driver mutations across all 11 patients in sub-cohort C. (C) Clinical course for patient #29 who underwent an initial robotic supracervical hysterectomy and bilateral salpingectomy for a weakly ER/PR-positive uLMS and subsequent robotic assisted trachelectomy, infracolic omentectomy with bilateral pelvic lymph node dissection (not shown). A sample from a CT-guided biopsy the following year was used to build a personalized ctDNA assay. She later received cytotoxic therapy, followed by a metastatic resection, and hormonal therapy.